Korean J Urol.  1990 Dec;31(6):869-873.

Clinical Effects of Serenoa Repens(Permixon) on Chronic Prostatitis

Affiliations
  • 1Department of Urology, Central Gil General Hospital, Inchon, Korea.

Abstract

Chronic prostatitis has various symptoms and many problems in management. Recently a lipidosterolic extract of Serenoa Repens, Permixon has been reported to reveal potential antiandrogenic and anti inflammatory activities on prostate. Then we used Permixon on chronic prostatitis and following results were obtained. Permixon is administered orally in dose of 160mg., b.i.d. for 60 days in 31 cases of chronic prostatitis in 1st group, Permixon 160mg, with Cipro-floxacin 500mg, b.i.d. in 35 cases in 2nd group and Placebo 2 tablets, b.i.d. in 30 cases in 3rd group. In 1st group 36 cases(77.4%) were improved, 29 cases(82.8%) in 2nd group and 7 cases (23.3 %) of 3rd group were improved. Permixon is an effective drug in chronic prostatitis and there was no changes in laboratory findings and negligible side effects were noticed

Keyword

Chronic prostatitis; Medical treatment

MeSH Terms

Prostate
Prostatitis*
Serenoa*
Tablets
Tablets
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr